Iacopo Chiodini MD

Iacopo Chiodini’s research career commenced in 1994, since which he has largely focused on the influence of endocrine disorders on bone metabolism, particularly in relation to overt and subclinical hypercortisolism. He is currently focusing on the diagnosis and therapy of subclinical hypercortisolism, the role of cortisol secretion in hypertension, diabetes and osteoporosis, and the involvement of bone in metabolic syndrome.

Iacopo Chiodini is co-author of more than 170 peer-reviewed papers (Scopus h-index 44). He has coordinated several studies on the effects of subclinical hypercortisolism in patients with adrenal incidentalomas, the role of the hypothalamic-pituitary-adrenal axis, and individual sensitivity to glucocorticoid excess in patients with diabetes and osteoporosis, as well as the effects of conservative or surgical approaches to treatment in patients with mild hypercortisolism. He is currently involved with several drug-development trials for the treatment of both overt and subclinical hypercortisolism and is a member of advisory boards that focus on hypercortisolism screening in high-risk populations.

Iacopo Chiodini has been speaker, or Chair, at more than 130 national and international meetings and Visiting Professor for subclinical hypercortisolism and adrenal incidentalomas at several renowned US institutions. These include the University of Central Florida, Orlando, FL; University of Michigan, Ann Arbor, MI; University of Arizona, Phoenix, AZ; Oregon Health & Science University, Portland, OR; University of California, Sacramento and San Diego, CA; Johns Hopkins Hospital, Baltimore, MD; Mount Sinai Hospital, New York, NY; Medical College of Wisconsin, Milwaukee, WI.

Iacopo Chiodini is Editor-in-Chief of the journal section Adrenal Endocrinology in Frontiers in Endocrinology and a member of the adrenal incidentaloma study group of ENS@T (the European Network for the Study of Adrenal Tumors). He is current President of the Italian Society for Osteoporosis and Metabolic Bone Diseases.

Disclosures: Iacopo Chiodini has served on advisory boards for HRA Pharma, Corcept Therapeutics, Eli- Lilly, Amgen, UCB, Abiogen, Theramex, and Sandoz and is currently involved with clinical trials for HRA Pharma and Corcept Therapeutics